Can-Fite BioPharma (CANF) Tops Q1 EPS by 63c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Can-Fite Reports First Quarter 2020 Financial Results & Provides Clinical Update
June 1, 2020 7:00 AM EDTCompany to host conference call at 8:30 a.m. ET today, June 1 Achieved efficacy and safety endpoints in Phase II NASH trial, with all cases of NASH significantly resolved after 12 weeks of treatment with 25 mg Namodenoson Pre-IND filed with FDA for clinical study of Piclidenoson in treatment of COVID-19 Interim results from Phase III Piclidenoson trial for psoriasis and rheumatoid arthritis expected Q4 2020
PETACH TIKVA, Israel--(BUSINESS... More
